Among those with advanced gastric cancer, oral Liporaxel showed superior overall survival outcomes versus IV Liporaxel as a ...

A phase 2 study to assess the safety and efficacy of FLX475 (tivumecirnon) combined with pembrolizumab in patients with advanced or metastatic gastric cancer. This is an ASCO Meeting Abstract from the ...

The phase 3 CheckMate 649 trial showed that nivolumab plus chemotherapy significantly improved long-term overall survival in ...

Early cancer symptoms often go unnoticed, leading to delayed diagnosis. Experts warn that persistent cough, unexplained ...

Shares of Leap Therapeutics (NASDAQ:LPTX) tumbled 64% in pre-open trading Tuesday as the company announced that its ...

Researchers compare nivolumab as monotherapy or in combination with chemotherapy vs conventional treatment on overall survival and progression-free survival in patients with advanced unresectable ...

This is the largest global assessment of the prevalence of FGFR2b protein overexpression in gastric cancers with potential clinical implications as an emerging target for gastric cancer. FORTITUDE-101 ...

Leap Therapeutics, Inc.'s DKN-01 trial results show mixed outcomes in cancer treatment, prompting potential future funding ...

Oral paclitaxel matched IV in progression-free survival but outperformed it in overall survival for second-line advanced gastric cancer.

The study, which enrolled 170 first-line, HER2-negative patients with advanced gastroesophageal junction (GEJ) and gastric cancer, compared the efficacy of sirexatamab in combination with ...